Studies show that the p16 genetic status is closely related to the stages of urinary bladder cancer, where the loss of p16 was seen in association with low-grade urothelial carcinoma, while amplified p16 denoted high-grade tumor [57]. Here, CDKN2A is linked to neoplasm.